Recruiting PHASE2 INTERVENTIONAL 1-arm
NCT07276386
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
Phase 2 Sequential Treatment With Melphalan/HDS Via Percutaneous Hepatic Perfusion Followed by Tebentafusp in the Treatment of Metastatic Uveal Melanoma
Sponsor: Delcath Systems Inc.
Conditions
Metastatic Uveal Melanoma
Interventions
Melphalan/HDS (Percutaneous Hepatic Perfusion) Tebentafusp
Updated 1 time since 2026 Last updated: Dec 1, 2025 Started: Dec 31, 2025 Primary completion: Dec 31, 2030 Completion: Dec 31, 2030
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE2 trial investigates Metastatic Uveal Melanoma and is currently actively recruiting participants. Delcath Systems Inc. leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
1 version recorded Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Delcath Systems Inc.
- H. Lee Moffitt Cancer Center and Research Institute
Data source: H. Lee Moffitt Cancer Center and Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .